Compare Datadog Inc (DDOG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Novo Nordisk A/S — how do they compare? Datadog Inc trades at $293.26 (market cap $98.31B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Novo Nordisk A/S for 116 Days on average.
| DDOG | NVO | |
|---|---|---|
Market Cap | $98.31B | $165.31B |
Volume | 2,936,660 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $288.15 | $63.98 |
52-Week Low | $102.62 | $35.29 |
Typical Hold Time | 76 Days | 116 Days |
Enterprise Value | $94.61B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $273.80, up 0.91% today, and is approaching its consensus price target of $276.10. The stock exhibits a bullish technical trend, supported by strong moving averages, while recent earnings have consistently beaten expectations. Revenue growth remains robust, projected to reach $4.0 billion in 2026, though net margins are volatile. Positive analyst sentiment, with 83% buy ratings, reflects confidence in the company's AI and enterprise expansion.
The outlook for DDOG is favorable given accelerating AI adoption and international growth, but high valuation multiples (P/E 547.6) pose a risk if growth slows. Investor sentiment is buoyed by strategic positioning in cloud observability, yet competition and customer spending pressures remain key watchpoints for sustained upside.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
